These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28841868)

  • 1. A systematic review of the effectiveness of policies restricting access to pregabalin.
    Stacey BR; Liss J; Behar R; Sadosky A; Parsons B; Masters ET; Hlavacek P
    BMC Health Serv Res; 2017 Aug; 17(1):600. PubMed ID: 28841868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans.
    Margolis JM; Cao Z; Onukwugha E; Sanchez RJ; Alvir J; Joshi AV; Mullins CD
    Am J Manag Care; 2010 Jun; 16(6):447-56. PubMed ID: 20560688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of pharmacoeconomic studies for pregabalin.
    Parker L; Huelin R; Khankhel Z; Wasiak R; Mould J
    Pain Pract; 2015 Jan; 15(1):82-94. PubMed ID: 24815038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.
    Udall M; Louder A; Suehs BT; Cappelleri JC; Joshi AV; Patel NC
    J Med Econ; 2013; 16(6):784-92. PubMed ID: 23565813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a pregabalin step therapy policy among medicare advantage beneficiaries.
    Suehs BT; Louder A; Udall M; Cappelleri JC; Joshi AV; Patel NC
    Pain Pract; 2014 Jun; 14(5):419-26. PubMed ID: 23701733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior authorization in the treatment of patients with pDPN and FM.
    Placzek HE; Masters ET; Gu T; Cappelleri JC; Wasser TE; Clair AG; Cook JP; Eisenberg DF
    Pain Pract; 2015 Jan; 15(1):E9-19. PubMed ID: 25387598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
    Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
    BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.
    Navarro A; Saldaña MT; Pérez C; Torrades S; Rejas J
    BMC Neurol; 2011 Jan; 11():7. PubMed ID: 21251268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care Costs.
    Martin C; Odell K; Cappelleri JC; Bancroft T; Halpern R; Sadosky A
    J Manag Care Spec Pharm; 2016 Feb; 22(2):132-44. PubMed ID: 27015252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Medication Use in Patients with Postherpetic Neuralgia.
    Gudin J; Fudin J; Wang E; Haylon T; Patel K; Goss TF
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1387-1396. PubMed ID: 31589557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a Medicaid prior authorization policy for pregabalin.
    Margolis JM; Johnston SS; Chu BC; Onukwugha E; Hvidsten K; Alvir J; Rossi JG; Mullins CD
    Am J Manag Care; 2009 Oct; 15(10):e95-102. PubMed ID: 19817512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Concomitant Pain Medications on Response to Pregabalin in Patients with Postherpetic Neuralgia or Spinal Cord Injury-Related Neuropathic Pain.
    Schug SA; Parsons B; Almas M; Whalen E
    Pain Physician; 2017; 20(1):E53-E63. PubMed ID: 28072797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin.
    Johnson P; Becker L; Halpern R; Sweeney M
    Clin Drug Investig; 2013 Jan; 33(1):35-44. PubMed ID: 23179473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
    Ritchie M; Liedgens H; Nuijten M
    Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
    J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.
    Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Páramo M; Navarro-Artieda R
    J Eval Clin Pract; 2017 Apr; 23(2):402-412. PubMed ID: 27671223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
    Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
    Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.